ReviewFrontiers in oncology2018
Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Pretreatment Prediction of Tumor Recurrence in Breast Cancer After Neoadjuvant Systemic Therapy Using Machine Learning With Clinical and CT Radiomics Features.The Kaohsiung journal of medical sciences · 2026Article
- Postoperative wound microenvironment regulates breast cancer stem cell fate and clinical implications.Molecular biology reports · 2026Review
- Recurrence Patterns in Breast Cancer: A Single-Center Retrospective Analysis.Journal of clinical medicine · 2025Article
- Machine learning prediction of breast cancer local recurrence localization, and distant metastasis after local recurrences.Scientific reports · 2025Article
- One-week external beam partial breast irradiation: survival and toxicity outcomes.Journal of cancer research and clinical oncology · 2023Article
- Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study.World journal of surgical oncology · 2023Article
- Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases.Communications biology · 2023Article
- Outcomes of breast conserving therapy: Recurrence, imaging findings and histological correlation.SA journal of radiology · 2023Article
- Review
- Short- and long-term recurrence of early-stage invasive ductal carcinoma in middle-aged and old women with different treatments.Scientific reports · 2022Article
- Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.International journal of radiation oncology, biology, physics · 2021Review
- Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset.Breast cancer research and treatment · 2021Article
- Elucidating cancer-vascular paracrine signaling using a human organotypic breast cancer cell extravasation model.Biomaterials · 2021Article
- Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis.Cancer management and research · 2021Article
- Prognostic values of EDNRB in triple-negative breast cancer.Oncology letters · 2020Article
- Adaptive radiation therapy of breast cancer by repeated imaging during irradiation.World journal of radiology · 2020Review
- Comparison of unsupervised machine-learning methods to identify metabolomic signatures in patients with localized breast cancer.Computational and structural biotechnology journal · 2020Article
- Reirradiation of recurrent breast cancer with proton beam therapy: A case report and literature review.World journal of clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolated local or regional recurrence of breast cancer (BC) leads to an increased risk of metastases and decreased survival. Ipsilateral breast recurrence can occur at the initial tumor bed or in another quadrant of the breast. Depending on tumor patterns and molecular subtypes, the risk and time to onset of metastatic recurrence differs. HER2-positive and triple-negative (TNG) BC have a risk of locoregional relapse between six and eight times than luminal A. Thus, the management of local and locoregional relapses must take into account the prognostic factors for metastatic disease development. It is important to personalize the overall management, including or not systemic treatment according to the metastatic risk. All isolated recurrence cases should be treated with curative intent. Complete surgical resection is recommended whenever possible. Patients who did not receive postoperative irradiation during their initial management should receive full-dose radiotherapy to the chest wall and to the regional lymph nodes if appropriate. Overall, total mastectomy is the "gold standard" among patients who were previously treated by conservative surgery followed by radiation therapy. In terms of systemic therapy, the benefits of additional treatments are not conclusively proven in cases of isolated recurrence. The beneficial role of chemotherapy has been reported in at least one randomized trial, while endocrine therapy and anti-HER2 are common practice. This review will discuss salvage treatment options of local and locoregional recurrences in the new era of BC molecular subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.